Here, we verified the molecular mechanisms of FLT3-driven drug resistance, optimized methods for the detection of FLT3 protein expression and cellular localization, the correlation between FLT3 and CML prognostic factors, and the therapeutic strategies to tackle FLT3+ CML patients. This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.